CRBU vs. FHTX, PSTX, GLUE, SOPH, CLLS, IMTX, HUMA, INBX, RLAY, and MESO
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Foghorn Therapeutics (FHTX), Poseida Therapeutics (PSTX), Monte Rosa Therapeutics (GLUE), SOPHiA GENETICS (SOPH), Cellectis (CLLS), Immatics (IMTX), Humacyte (HUMA), Inhibrx (INBX), Relay Therapeutics (RLAY), and Mesoblast (MESO). These companies are all part of the "medical" sector.
Caribou Biosciences (NASDAQ:CRBU) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation.
In the previous week, Caribou Biosciences had 8 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 8 mentions for Caribou Biosciences and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.00 beat Caribou Biosciences' score of -0.59 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.
Foghorn Therapeutics has a net margin of -274.23% compared to Caribou Biosciences' net margin of -345.05%. Foghorn Therapeutics' return on equity of 0.00% beat Caribou Biosciences' return on equity.
Caribou Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500.
Foghorn Therapeutics received 14 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 59.26% of users gave Foghorn Therapeutics an outperform vote while only 52.94% of users gave Caribou Biosciences an outperform vote.
Foghorn Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Caribou Biosciences currently has a consensus target price of $15.25, indicating a potential upside of 619.34%. Foghorn Therapeutics has a consensus target price of $14.50, indicating a potential upside of 133.87%. Given Caribou Biosciences' higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Foghorn Therapeutics.
Summary
Caribou Biosciences and Foghorn Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
